Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
we'll see 8 by summer.IMO
it's weak today.
I'll take a couple % gains daily .lol
it's ready to explode.
Pre-market 2.47 with 8650 shares traded ..i'm not sure if this means anything.
I 've been adding a few K here and there.Thanks
Thanks for the reply.What's your target for this stock?
ANV really had a monster run.
What's the story on their permit? Please fill me in some details.TIA
Goldcorp to buy Andean Resources for $3.42 billion
By ROB GILLIES (AP) – 16 minutes ago
TORONTO — Canada's Goldcorp Inc. said Friday it has agreed to buy Andean Resources Ltd. for about 3.6 billion Canadian dollars (US$3.42 billion), trumping a rival bid from Eldorado Gold Corp.
The acquisition would give Goldcorp, the world's second-largest gold producer by market capitalization, access to Andean's Cerro Negro gold project in Argentina, which is said to have a significant amount of gold and silver.
The Goldcorp-Andean deal has been approved by both companies' boards but requires approval by a majority of Andean shareholders. The companies expect the deal to close later this year or in early 2011.
The announcement came shortly after Canada's Eldorado made an offer of 3.4 billion Canadian dollars (US$3.2 billion) for the company.
Andean is based in Utah and is listed on the Toronto and Australian stock markets. It acquired the Cerro Negro gold deposit in southern Argentina in 2004.
Wayne Hubert, Andean's CEO, said the Goldcorp deal benefits both companies and allows for the development of Cerro Negro into a key gold project.
"The Andean board of directors strongly believes that the shareholders of both parties will benefit from this business combination well into the future," Hubert said in a statement.
Under terms of the Goldcorp deal, each Andean common share will be exchanged for 0.14 Goldcorp shares or a cash payment in the amount of 6.50 Canadian dollars ($6.17) per share.
The maximum cash consideration will be 1 billion Canadian dollars ($948.6 million).
Shareholders can choose stock, cash or a combination of the two.
Paul Wright, president and CEO of Eldorado, said Eldorado had been looking at buying Andean for the past two years and had taken its offer to shareholders after the companies failed to reach an agreement.
Earlier this year, Goldcorp also beat out Barrick Gold Corp., the world's largest gold producer, when it bought a controlling interest in the El Morro gold-copper project in Chile from junior miner New Gold Inc.
Andean's Cerro Negro gold project has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver.
"This transaction adds another key asset to Goldcorp's peer-leading growth profile and low-cost gold production pipeline," the company's president and CEO, Chuck Jeannes, said in a statement.
Jeannes added that the project allows Goldcorp to increase its gold resources by expanding existing deposits and exploring more areas that may have additional deposits.
If the transaction doesn't close, Andean will pay Goldcorp a termination fee equal to 1 percent of the aggregrate total offer made by Goldcorp.
Copyright © 2010 The Associated Press. All rights reserved.
I added another 7K shares at 4.16.No guts no glory who ever sold today will regret it later .This BS is just noise.IMO
I'm not seeing any mention about BSPM. The PPS is crushed because of one lousy BS rumor.
http://translate.google.com/translate?js=y&prev=_t&hl=en&ie=UTF-8&layout=1&eotf=1&u=http%3A%2F%2Fwww.qmyy.com%2Fnews%2Falone_news_show.aspx%3Fid%3D20100422000084&sl=zh-CN&tl=en
One PR from the company and it will pop back to 5.IMO
This is pure BS.Use this as an opportunity to add.IMO
The big boys are coming.it will run hard with the small float.
The Company is on track to complete its vertical integration process and expects its zinc & aluminum galvanizing steel production system, which could operate both hot-rolled and cold-rolled coils, with a designed annual manufacturing capacity of 400,000 metric tons to become operational by the end of February 2008..."
Huge block came in.
It's consolidating and building a base .This baby is primed to take off from here.You need to calm down >things are looking good.The next pop will be the Mexico or US news'.BUY more if you can afford.IMO
BluePhoenix Announces Recent $4 Million Modernization Contract Win at a Major U.K. Government DepartmentLast update: 2/5/2008 8:32:00 AMRepresents Continued Market-Leading Success in Penetrating the Fujitsu ICL Mainframe Market Contract in Close Cooperation With One of the Largest Global System Integrators Implementation Will Enable an Enterprise Data Warehouse, Yielding Far Reaching Benefits Through the Smarter Use of Data, Such as Increasing Efficiencies HERZLIYA, Israel, February 5, 2008 /PRNewswire-FirstCall via COMTEX/ -- BluePhoenix Solutions (BPHX), the leader in value-driven legacy modernization, today announced that it has won a major contract valued at around $4 million with a UK Government Department. The contract was signed with one of the leading global system integrators. Organizations that have mission critical systems running on Fujitsu ICL mainframes are facing growing risks and costs. Diminishing availability of tools and resources are compelling many companies to modernize this aging platform. Many Fujitsu ICL systems have been in place for over 25 years. BluePhoenix's market-leading solution for Fujitsu ICL includes a highly automated toolset that migrates data stores from IDMSX to Oracle, SQL Server or DB2. In addition, our solutions enable Fujitsu ICL applications to be modernized to .Net, UNIX or Linux platforms. These projects are often complex due to the age and size of the typical Fujitsu ICL application. BluePhoenix's tools will be used to modernize the Department's data stores from IDMSX on the Fujitsu ICL mainframe to Oracle running on Sun UNIX, and to perform daily synchronization. The major goal of the project is to streamli
This contract represents another large win for BluePhoenix in the government vertical and around the Fujitsu ICL mainframe computing platform," said Arik Kilman, CEO of BluePhoenix. "BluePhoenix offers ICL customers reliable, low-risk and cost-effective modernization providing a combination of technology, expertise and services. We have proven experience in this area with excellent references." Fujitsu ICL computers can be found in leading UK public sector organizations, military and defense and large financial institutions. For more information
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={DBD98A25-D13D-4B37-BEB7-B9B83071B32A}
China Biopharma Growing at "China Speed"
posted on: January 21, 2008 | about stocks: ACCP.OB / BPMA.OB / CBPO.PK / VSCO.OB Print Email In China biopharma news last week, there were two items of broad significance and a host of company-specific announcements. The pace of growth in China biopharma seems to be picking up, as the industry lives up to the often used term “China Speed.”
Perhaps the report with the most far-reaching significance was a story about the as-yet unannounced 11 billion RMB ($1.5 billion) initiative of China’s government to stimulate a native innovative drug sector (see story). China’s cabinet, the State Council, is reported to have approved the program in late December, but has not made any formal declarations about the plan so far.
According to the latest rumors, the program will be formally announced in March. The money, which will be dispensed in addition to current programs, will be spent over 15 years at roughly the rate of about $100 million per year: 4 billion RMB ($548 million) over the next five years and 7 billion RMB ($966 million) in the following 10 years.
ChinaBio Today also continued its four-part coverage of proposed changes in the Chinese patent system, another story with broad significance (see story). This article, written by Dr. Charles C. Liu, Partner of the Unitalen firm, and Jeanne J. Liu, declares that innovative companies will be “profoundly touched” by the proposed alterations in patent law and practice. In this second of four installments, the authors discuss the specific topics of "Design Patents," and "Division Applications."
Last week, the ranks of China biopharmas that trade on US exchanges was increased by one, as Chengdu Tianyin Pharmaceutical Co. Ltd. used a reverse merger with VisCorp (VSCO.OB) to make its debut as public company (see story). At the same time, Chengdu Tianyin closed a $10.2 million private placement. As a revenue-producer, Tianyin Pharmaceutical Co., as the new company will be known, is no slouch. In fiscal 2007 (which ended on June 30), the company made a $4.2 million profit on revenues of $20.4 million. Tianyin currently markets 34 products and has another 51 awaiting approval from the SFDA.
Two CROs announced that they closed additional venture capital rounds last week. Sundia MediTech Company, a Shanghai-based CRO, completed a B series (see story). According to Sundia officials, the fund raising was facilitated by the highly successful IPO of WuXi PharmaTech (WX) last summer. Because that offering was so warmly received, China CROs suddenly became very visible and desirable. Sundia had some publicity of its own: the company was ranked number 16 on the respected Venture 50 list, a ranking of the most promising investment opportunities in China put together by investment house Zero2IPO. Last year, Sundia merged with fellow Shanghai CRO, United PharmaTech.
A second CRO, Bridge Laboratories, headquartered in the US, but with its original pre-clinical lab in Beijing, closed $18 million in a third round (see story). Bridge will use the money to expand its Beijing toxicology lab, and to make acquisitions. The latest round brings Bridge’s totally funding to $57 million. Investors in the Series C include the previous investors in the Series B funding and several new global investors, including Granite Global Ventures [GGV]. Granite Global will put one of its Shanghai-based founders on Bridge’s board.
Benda Pharmaceutical (BPMA.OB) will seek to migrate from the OTC Bulletin Board to the American Stock Exchange (see story) . The company has also established a relationship with CRT Capital Group LLC to explore strategic alternatives, including M&A, joint venture, divestiture, spin-off, financing or other capital market transactions, a companion initiative to the AMEX listing. In April 2007, Benda bought a 60% share of SiBiono and its gene therapy cancer drug Gendicine. Part of the deal sent 2.2 million unregistered shares to SiBiono owners. Benda promised the investors that the shares would be registered on the NASDAQ or AMEX and that they would have a price of $3.60 each by mid-2008. Otherwise, Benda has to buy the shares back from the shareholders at $3.60. Because Benda is languishing below $1 per share, it will also need to find some cash.
Access Pharma (ACCP.OB) out-licensed the China rights to MuGard, its oral mucositis product, to RHEI Pharma (see story). RHEI, which is based in the US, is in the business of taking proprietary medications to China, shepherding them through the SFDA approval process, and then distributing them. If MuGar is granted approval, RHEI will manufacture the product in China and, hopefully, then distribute MuGard throughout Southeast Asia.
China Biologic Products (CBPO.PK) was awarded a relatively small provincial grant of 1.5 million RMB ($200,000) that it will use to upgrade its plasma production facilities (see story). In 2007, plasma-based drugs have seen huge run-ups in prices because the supply of raw plasma was curtailed when regulators found tainted supply. The Shandong Provincial government bestowed the grant on China Biologic as part of their Double Hundred project. The project is meant to encourage technologically innovative industries. In the first nine months of 2007, China Biologic produced a profit of $7.6 million on revenues of $25.4 million.
And also last week in ChinaBio Today, we reviewed the success of the ChinaBio Investor Forum, put together in just six weeks, but a major success despite its short gestation period (see story). Early state biotech companies presented their stories to leading VCs, and some deals have already been struck. “China Speed” is the term used to describe the sometimes near-miraculous velocity at which things get done in China, and the ChinaBio Investor Forum showed that “China Speed” is no myth: it's a fact.
Disclosure: none.
I've been accumulating Accp on dips since spring of 07.I think it will be a monster year for us Longs.
ACCP ...Yep , EUROPE ..CHINA ..an US partner will be next then AFRICA.
ACCP .Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian CountriesLast update: 1/14/2008 8:30:00 AMDALLAS and NEW HAVEN, Conn., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory. "We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace." "RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGard in this region. We believe MuGard will fit very well with their existing portfolio of products and benefit from their aggressive marketing programs. We are also excited about the efficiency RHEI will obtain by manufacturing MuGard in their own GMP facility." About MuGard(TM):
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={FC51DA6F-D0B1-4D75-9BA4-AFB9CE869139}
ACCP has huge news !!!!!
Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian CountriesLast update: 1/14/2008 8:30:00 AMDALLAS and NEW HAVEN, Conn., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory. "We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace." "RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGard in this region. We believe MuGard will fit very well with their existing portfolio of products and benefit from their aggressive marketing programs. We are also excited about the efficiency RHEI will obtain by manufacturing MuGard in their own GMP facility." About MuGard(TM):
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={FC51DA6F-D0B1-4D75-9BA4-AFB9CE869139}
ACCP has huge news !!!!!
Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian CountriesLast update: 1/14/2008 8:30:00 AMDALLAS and NEW HAVEN, Conn., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory. "We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace." "RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGard in this region. We believe MuGard will fit very well with their existing portfolio of products and benefit from their aggressive marketing programs. We are also excited about the efficiency RHEI will obtain by manufacturing MuGard in their own GMP facility." About MuGard(TM):
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={FC51DA6F-D0B1-4D75-9BA4-AFB9CE869139}
ACCP has huge news !!!!!
Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian CountriesLast update: 1/14/2008 8:30:00 AMDALLAS and NEW HAVEN, Conn., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory. "We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace." "RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGard in this region. We believe MuGard will fit very well with their existing portfolio of products and benefit from their aggressive marketing programs. We are also excited about the efficiency RHEI will obtain by manufacturing MuGard in their own GMP facility." About MuGard(TM):
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={FC51DA6F-D0B1-4D75-9BA4-AFB9CE869139}
gap up BID (3) 20.4, ASK (10) 20.75
NP , I have live news.ARAY is finally on the radar.GLTU
Accuray Enters Partnership with Still River SystemsLast update: 10/30/2007 8:30:00 AMAccuray to Provide Robotic Patient Positioning System for Lower Cost Proton Therapy Solution SUNNYVALE, Calif., Oct 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- Accuray Incorporated (ARAY), a global leader in the field of radiosurgery, announced today that the company has entered into a partnership with Still River Systems, developer of high quality, cost-effective proton beam radiotherapy solutions, and will provide them with a robotic patient positioning system. Accuray will supply a version of its RoboCouch(R) Robotic Patient Positioning System, which intelligently positions patients with 6 degrees of freedom for treatment, enabling clinicians to automatically re-position the patient from the control room. The patient positioning system will be used with Still River Systems' Monarch 250(TM) PBRT System, a practical, cost- efficient, single-room proton beam radiotherapy (PBRT) system scaled for use at most cancer centers. "We are pleased that Still River Systems recognizes Accuray's prominent position in the field of medical robotics and has chosen us to develop their patient positioning system," said Chris Raanes, senior vice president and chief operating officer of Accuray Incorporated. "Accuray's technologies are precise and will allow the Monarch 250 System to provide optimal patient positioning accuracy and comfort." "As it is well recognized that precise positioning is required to gain the advantages of proton therapy, we are excited to work with Accuray to bring new standards of excellence to positioning patients for these treatments," said Marc Buntaine, CEO of Still River Systems. "With our Monarch 250 System including a custom version of the RoboCouch, physicians will be able to quickly and precisely position patients in correct translation and rotational alignment for each proton treatment fraction."
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={6D20C16D-C7A7-4DB5-B3B3-DD3D84570119}
Accuray Enters Partnership With Still River SystemsLast update: 10/30/2007 8:35:25 AM(MORE TO FOLLOW) Dow Jones NewswiresOctober 30, 2007 08:35 ET (12:35 GMT
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={C8C379D7-18E6-4185-9D80-BEAE868B9BBD}
Accuray Announces Four New Products at Nation's Leading Radiation Oncology MeetingLast update: 10/29/2007 3:00:00 PMNew CyberKnife Technologies Improve Treatment Times, Optimize Planning Objectives and Offer Increased Clinical Flexibility in Radiation Delivery SUNNYVALE, Calif., Oct 29, 2007 /PRNewswire-FirstCall via COMTEX/ -- Accuray Incorporated (ARAY), a global leader in the field of radiosurgery, announced today four new products designed to improve treatment times, optimize treatment planning objectives and offer greater clinical flexibility in radiation delivery. These products are being launched at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles. Iris(TM) Variable Aperture Collimator In radiosurgery, clinicians can define the amount, or dose, of radiation delivered during treatment using a collimator -- a metal radiation blocking device with an opening that dictates the shape and size of the radiation beam. In the past, when clinicians wanted to use multiple collimators to vary the size and shape of their radiation beam it required they manually switch out collimators in the middle of treatment. With the launch of the CyberKnife System's Xchange(TM) Robotic Collimator Changer at ASTRO 2006, the process of changing collimators became automated, eliminating the need to re-enter the treatment room, which minimizes related treatment delays. Now the process for using multiple collimators has become even more streamlined with the introduction of the Iris(TM) Variable Aperture Collimator, which no longer requires the removal of a collimator because it can automatically alter the size of its opening to let radiation beams of 12 discreet sizes pass through. The Iris Collimator allows the CyberKnife System to efficiently deliver different sized beams from each treatment position (as opposed to delivering with one collimator size from many positions, then switching to a new size to deliver from many positions, then switching to the next size and so on). This makes multiple collimator sized treatments much faster, allowing clinicians to safely deliver such a treatment in as little as half the time. The Iris Collimator enables clinicians to create and deliver practical multi-collimator treatments that have greater accuracy, more uniformity and better avoidance of nearby critical structures and healthy tissue than single collimator treatments. 800 MU/min LINAC Currently the CyberKnife System features a compact linear accelerator capable of delivering 600 monitor units per minute. A monitor unit (MU) is the measure of machine output for a linear accelerator (LINAC) in radiation therapy and radiation dose rate typically is measured in MU/minute. Accuray is announcing the introduction of an 800 MU/min LINAC, which is capable of delivering higher dose rates of radiation to a tumor, thereby reducing treatment times. This advanced new 800 MU/min linear accelerator system will not only be incorporated into the current CyberKnife offering, it will also serve as the platform for future technologies. Sequential Optimization Planning Tool The Sequential Optimization feature is an optimization capability that will now be available as a software option for the MultiPlan(R) Treatment Planning System. The technology allows users to optimize their treatment objectives based on each unique clinical situation using prioritized clinical objectives, instead of the traditional trial and error setting of various constraints to narrow in on an optimized treatment. This enables users to establish their own clinical objectives to achieve high quality, more intuitive treatment planning in a shorter amount of time. RoboCouch(R) Patient Positioning System with Seated Load The RoboCouch(R) Patient Positioning System with a new seated load capability is a more comfortable and ergonomic treatment couch, developed with mobility challenged patients in mind. The seated load feature offers easier loading and unloading capabilities and provides added comfort for the unique needs of wheelchair bound or disabled patients. Its flexible design has a built in adjustable knee bolster improving patient comfort while also allowing treatments to be performed either with the patient's knees bent and up or in a completely flat table top configuration. In addition, because patients are more comfortable during treatment, the system minimizes patient motion resulting in fewer treatment interruptions. While these technologies will positively impact CyberKnife treatments across many indications, they are especially important in the treatment of lung and prostate cancer because they offer the flexibility to tailor treatment with different clinical objectives to each patient -- whether the priority is conformality, homogeneity, reduced dose delivery or some combination -- all while reducing radiation dose to the surrounding critical structures. Additionally, the combination of these technologies will improve patient comfort, speed up treatment delivery and planning times, and improve the accuracy of delivered treatments ultimately ensuring that the right dose is delivered to the right place at the right time. "At Accuray our focus is delivering clinically significant technologies to our current and future CyberKnife System users," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "At this year's ASTRO, we are delighted to be able to launch these four new innovations that not only better meet our clinicians' needs for faster, more flexible radiation optimization, but also enhance their patients' treatment experience." About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively and with sub-millimeter accuracy. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver precise, high-dose radiation, minimizing damage to surrounding healthy tissue and eliminating the need for invasive head or body stabilization frames. About Accuray Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 35,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Amer
JC didn't pump ARAY but he sure did help put it on the radar.
I think it's a bargain here . The PPS for the PP for 4 Millions shares was $1.5 .This stock will take off when they announced the Sports Authority news and the MSRX' IPO .IMO
"HealthSport Closes $6 Million Fixed Price Private Placement
May 18, 2007 11:52:00 AM
AMHERST, NY and WOODLAND HILLS, CA -- (MARKET WIRE) -- 05/18/07 -- HealthSport, Inc. (OTCBB: HSPO), a fully integrated developer, manufacturer and marketer of unique and proprietary branded and private label edible film strip nutritional supplements and over-the-counter drugs, announced today it has closed a private placement of its shares of common stock in which the Company received total net proceeds of $6 million. Under the terms of the placement, HealthSport sold approximately 4 million shares of common stock at a fixed price of $1.50. The shares underlying the placement carry registration rights calling for the filing of an SB-2 on or before June 1, 2008. Investors in the financing include former NFL stars Bruce Smith, Bernie Kosar and Jim Kelly. "
Yes ,the margin improved with less rev.Like i said it's just a speed bump.Next Q if they get their act together we'll have a blowout Q and that might be the catalyst to move it to new high.
Sometime it 'd take more than 3 months to work out the kinks in construction .It' just a speed bump.KSW will be higher by eoy .I love to see low 6 so i can add another 50K.
I 'm adding.Next Q KSW will a lot higher.IMO
KSW is a solid stock /comp and will reach $15 sometime this year.IMO
Hi Norwerger,I haven't heard from you in awhile.I thought you were on vacation again with your profits,lol.
You're right we have to add the 5% split adj.It's not a big deal.
KSW is on the Highest ranking stocks on the Composite IBD scale (best overall for the last few days.
I shorted 5000 shares of DECK av 105.9 yesterday.
VG,
From the 8K
ITEM 7.01. REGULATION FD DISCLOSURE
On March 14, 2006, the Company issued a press release announcing that
Floyd Warkol, its Chairman and Chief Executive Officer, has entered into a stock
trading plan intended to qualify for the safe harbor under Rule 10b5-1 under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"). Rule 10b5-1
permits officers and directors of public companies to enter into predetermined
plans for selling specified amounts of stock. The plans may be entered into only
when the director or officer is not in possession of material non-public
information. Under the plan Mr. Warkol authorized the sale of up to 400,000
shares of the Company's common stock owned by Mr. Warkol, 200,000 of which are
issuable upon the exercise of stock options, over the course of the next two
years. The plan provides for sales of up to specified numbers of shares within
specified ranges, subject to certain limitations. Sales pursuant to this plan
are intended to be disclosed publicly through Form 144 and Form 4 filings with
the Securities and Exchange Commission as required.
He's done selling this Q.The way i figured JPM will sell the remain 100 K shares in the next 2 Q (50 K shares ea Q = only 4 K each week ).Once the volume picks up we'll easily absorb those shares.IMO
Vg,I bot in march 06 and sold out in may 06.I got back in nov 06 and still have all my shares.KSW will be in the double digits soon or later.IMO
Hi Vg, i knew that site. Get some folks here to buy some shares .We've been flying under the radar for too long.
KSw was down because the momo traders jumped in and got stuck cuz there was'nt enough vol to push it higher so they sold out late in the day and pushed it lower.
It sould move up nicely now with 2 good contracts and no selling pressure left.IMO